Figure 5.

Adoptively-transferred allogeneic Vγ9Vδ2 T cells efficiently eliminate invasive GBM-10 primary tumor cells (A) GBM-10 cells were pretreated overnight with different concentrations of zoledronate, loaded with ⁵¹Cr and then co-cultured 4 h with Vγ9Vδ2 T cells (E/T ratio: 10/1). ⁵¹Cr release was measured in culture supernatants and the results are expressed as % cytotoxicity (mean ± SEM, n = 3). (B) Survival curves of GBM-10 brain tumor-bearing NSG mice treated, or not (— ; n = 10), with single injection (day 7) of zoledronate (---•--- ; n = 7), Vγ9Vδ2 T cells (---▪--- ; n = 7) or both (---★--- ; n = 10), or with double injections (days 7 and 14) of zoledronate (—•— ; n = 7), Vγ9Vδ2 T cells (—▪— ; n = 7) or both (—★— ; n = 10). Statistical analysis was performed by log-rank test compared with control (see the indicated p value).